What this means
This trial plans to test four doses of a supplement against a placebo and a similar supplement, NMN. It has not started yet and has no results, so it cannot yet show whether the supplement works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 40–70 · 60 healthy adults aged 40 to 70
- Where
- 1 site
The science
- Registered title
- Effects of Trigonelline Monohydrate on NAD+ Metabolism, Pharmacokinetics, Safety, and Tolerability in Healthy Adults
- Trial ID
- NCT07880925 ↗
- Phase
- PHASE 1
- Study type
- interventional
- Conditions
- NAD+ Metabolism, Pharmacokinetics, Bioavailability, Healthy Adults
- What is tested
- Nicotinamide Mononucleotide (NMN), Placebo, Trigonelline Monohydrate
- Sponsor
- dsm-firmenich Switzerland AG
- Ages
- 40 Years to 70 Years
- Dates
- First posted Oct 19, 2026 · updated Oct 19, 2026
Registry summary
This Phase 1 study is designed to evaluate the pharmacokinetic, pharmacodynamic, bioavailability, safety, and tolerability effects of trigonelline monohydrate in generally healthy adults aged 40 to 70 years. Sixty participants will be randomized in a double-blind, parallel-arm study to receive one of four doses of trigonelline monohydrate (equivalent to 150 mg, 300 mg, 450 mg, or 600 mg of trigonelline daily), an active comparator (600 mg nicotinamide mononucleotide [NMN]), or placebo for 4 weeks.
The primary objective is to assess the effect of trigonelline monohydrate supplementation on NAD+ metabolism by measuring the change from baseline in whole blood NAD+ concentrations after 4 weeks of supplementation. Secondary objectives include evaluation of trigonelline pharmacokinetics, bioavailability, plasma accumulation following repeated dosing, effects on NAD-related metabolites, and urinary excretion of trigonelline and NAD-related metabolites. Safety and tolerability will be assessed through adverse events, vital signs, anthropometric measurements, and clinical laboratory assessments. Exploratory analyses will examine inflammatory biomarkers and additional NAD-related metabolic outcomes.
Sites (1)
- Apex Trials, Guelph, Ontario - on, Canada